Fosun Pharma announces postponement of merger

Shanghai Fosun Pharmaceutical (Group) Co (Hong Kong:2196) released an update.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced a delay in submitting a key document relating to its proposed privatization of Henlius through a merger. The delay is due to the need for additional time to satisfy pre-conditions, such as obtaining government approvals. Investors are cautioned that the completion of the merger is conditional upon the satisfaction of these conditions.

For more information on HK:2196 stock, visit TipRanks Stock Analysis Page.